Overview

Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is intended to show whether inhaled chemotherapy can be added to a standard IV chemotherapy regime, to investigate the additional toxicities and to show initial evidence of efficacy of the combination.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zivena
Treatments:
Cisplatin
Docetaxel
Doxorubicin
Liposomal doxorubicin